Navigation Links
New Data Demonstrate Longer-Term Safety Profile of Esbriet®
Date:9/26/2011

AMSTERDAM, Sept. 26, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today reported that new data(1) was presented at the European Respiratory Society (ERS) Annual Congress supporting the longer-term safety and tolerability of Esbriet® (pirfenidone) in patients with idiopathic pulmonary fibrosis (IPF), a devastating lung disease.  Approximately 30,000-35,000 new IPF patients are diagnosed in Europe each year, with an estimated median survival of only two to five years. The announcement follows the recent marketing authorization of Esbriet in Europe and its first launch in Germany on 15 September.

Professor Ulrich Costabel, from the Department of Pneumology/Allergy at the Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany who presented the data, said: "These new data from the RECAP study show that the safety profile of pirfenidone remains consistent, even when pirfenidone treatment continued beyond three years, thereby adding to the growing body of evidence that supports the treatment of IPF with pirfenidone. This news should be welcomed by European clinicians who will soon have the opportunity to treat their mild to moderate IPF patients with this new medicine."

The RECAP extension study data, presented on 25 September at ERS, highlighted the positive longer-term safety and tolerability of Esbriet in patients with IPF. RECAP is an open-label extension study for patients who participated in the Phase 3 program for Esbriet, known as CAPACITY.  The CAPACITY program (studies 004 and 006) was designed to evaluate the treatment effect of Esbriet in IPF patients. In the CAPACITY studies, 779 patients were randomized to treatment with Esbriet or placebo and 626 patients completed the study. Of these, 603 (96 percent) were enrolled in RECAP.  

"IPF is a devastating condition with no proven management options other than
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
2. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
3. Germgard Lighting Demonstrates the Worlds Most Effective Hand Sterilizer to Protect Against Contagion
4. NIH-Funded Study Demonstrates That Patients Receiving New CPR Devices (ResQPOD® and ResQPump™) and Cooling Have Improved Long-Term Brain Function Following Cardiac Arrest
5. New Digital Linear Accelerator Control System Demonstrates Treatment Time Savings of Up to 30 Percent
6. Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
7. Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I
8. New Research Demonstrates High Prevalence of Sexually Transmitted Disease Trichomonas Vaginalis and Potential of New Molecular Test to Improve Detection
9. Topaz Pharmaceuticals Ivermectin Cream In Vitro Data Demonstrates Activity Against Head Lice Eggs
10. Halozymes Ultrafast Insulin Demonstrates Reduced Variability of Insulin Absorption for Type 1 Diabetes Patients Using Insulin Pumps
11. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Decrease Pancreatic Cancer Tumor Blood Flow and Reduce Blood Vessel Density
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WASHINGTON , Jan. 15, 2014 AARP Foundation today ... support older adults suffering from the severe cold weather that ... are committed to helping those in need; so to support ... dollar-for-dollar contributions up to $250,000, which could mean up to ...
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... WOONSOCKET, R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Texas--(BUSINESS WIRE)--Apr 3, 2007 - Repros,Therapeutics Inc. (NasdaqGM:RPRX) ... of Proellex(TM), an oral drug being developed to,relieve ... with Proellex results in a statistically highly,significant improvement ... well tolerated., Study Details and Results , This ...
... Arrowhead Research,Corporation (NASDAQ: ARWR) announced the publication ... a study,demonstrating the anti-proliferative effect of the ... its lead anti-cancer,compound, CALAA-01., The paper, entitled ... Reduce Cell Proliferation In vitro and In,vivo", ...
Cached Medicine Technology:Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 2Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 3Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 5Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study,Showing Anti-Cancer Effect with Lead RNAi Candidate 2Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study,Showing Anti-Cancer Effect with Lead RNAi Candidate 3
(Date:4/18/2014)... Ky. (April 21, 2014) -- A group of ... Medicine and the Sanders-Brown Center on Aging has ... depression and neuropsychological function in Parkinson,s disease (PD). ... Research , the study, which assessed cognitive function ... that the dopamine replacement therapy commonly used to ...
(Date:4/18/2014)... of Medicine researchers have been awarded two-year grants for ... announced this month. Of the 110 initial submissions to ... Forum Program, only four projects were funded, three of ... Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and ... professor of oncology, will use his $500,000 proof of ...
(Date:4/18/2014)... A new study in the American Journal of ... searches reveals a recurring pattern that could be leveraged ... from San Diego State University, the Santa Fe Institute, ... Google searches (searches that included the term healthy and ... U.S. from 2005 to 2012. They found that on ...
(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... published today in PLOS Pathogens , children who ... common can mount an immune response to infection with ... bouts of high fever and illness and partially control ... findings may help researchers develop future interventions that prevent ... , Each year, approximately 200 million cases of malaria ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2
... , , SACRAMENTO, Calif., July 21 If ... should be aware of California,s laws on pet safety. The California Veterinary ... safe. , , "There are a lot ... of the CVMA. "By taking a few precautions, travel with your companion pets ...
... , ST. LOUIS, July 21 Young ... of Directors declared a quarterly dividend of $0.04 per share, payable September ... Board of Directors also authorized the repurchase of up to 500,000 shares ... 2010 replaces the current authorization which is scheduled to expire on July ...
... , OAKLAND, Calif., July 21 ... owned by Tenet Healthcare Corporation organized an unprecedented national protest ... , , Tenet healthcare workers ... Association (NNOC/CNA) and Service Employees International Union (SEIU) Healthcare leafleted ...
... HIV transmission to infants via pre-chewed food suggest ... also a need for more data , ... have uncovered the first cases in which HIV almost certainly was transmitted from ... in the pre-chewed food was most likely the infected blood in the saliva ...
... right, exercised lowered chances of cardiovascular trouble , TUESDAY, July ... the right foods, exercising and losing weight pay off in ... show. , The reports, both originating at Brigham and Women,s ... of the Journal of the American Medical Association , ...
... , LANSING, Mich., July 21 The ... rushed timeline to address health care reform and urged Michigan,s ... and priorities. , , ... to work with Congress and the President to reform the ...
Cached Medicine News:Health News:Tips for Transporting Your Pet in California 2Health News:Young Innovations, Inc. Board of Directors Declares Quarterly Dividend and Authorizes Share Repurchase Program 2Health News:Tenet Nurses, Healthcare Workers Take Action to Protest Sick Leave Cuts 2Health News:Pre-chewed Food Could Transmit HIV 2Health News:Pre-chewed Food Could Transmit HIV 3Health News:Pre-chewed Food Could Transmit HIV 4Health News:Studies Affirm Value of Healthy Lifestyle 2Health News:Studies Affirm Value of Healthy Lifestyle 3Health News:Michigan Chamber of Commerce Raises Concerns With Flawed Federal Health Care Reform Proposal, Rushed Timeline 2
Incontinence Pessaries...
Incontinence Dish - Stress Incontinence with mild prolapse. Incontinence Dish with support - Stress Incontinence with mild prolapse and mild cystocele...
The donut pessary is designed for third degree prolapse as well as cystocele and rectocele. The soft donut can be compressed for insertion. It is available in seven sizes....
The Incontinence Dish is used to relieve stress incontinence and minor degrees of prolapse. The Incontinence Dish comes with and without support. It is available in eight different sizes....
Medicine Products: